Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus Rhamnosus in Congenital Heart Disease
NCT06872320Active, not recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, double-blind trial in congenital heart disease (CHD) and heart failure (HF) comparing Lactobacillus Rhamnosus with Placebo (2 arms). Primary endpoint: Percentile of body weight gain at 24 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
lactobacillus rhamnosus
03
Conditions
congenital heart disease (CHD)heart failure (HF)
Beyond the preview
Go deeper on NCT06872320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06872320.